+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

OKT3 induction in pediatric renal transplantation



OKT3 induction in pediatric renal transplantation



Pediatric Nephrology 7(1): 45-49



Twenty cadaveric renal transplant patients (mean age 12.5 +- 4.8 years) received 14 days (mean 13.0 +- 2.8 days) of OKT3 (mean dose 0.16 +- 0.09 mg/kg) along with prednisone 0.5 mg/kg per day, azathioprine 2 mg/kg per day and cyclosporine 5 mg/kg per day which was increased to obtain therapeutic levels before the discontinuation of OKT3. Actuarial patient and graft survival were 100% and 50%, respectively, at both 1 and 5 years. Four children lost their grafts within the first 48 h. One loss was technical in origin, the remaining 3 had pathological evidence of vascular thrombosis. Of the remaining 16 children, 12 (75%) experienced rejection episodes within the first 2 months post transplant (mean 27 +- 15 days). Successful reversal of early rejection episodes was achieved in 11 of 12 patients. Clinically significant cytomegalovirus infection occurred in 4 patients and resulted in graft loss in 2 patients. Circulating OKT3 levels ranging from 1,000 to 32,000 ng/ml were seen in all patients within the first 48 h. There was a rapid and total depletion of circulating CD3-positive lymphocytes in all patients. Antiisotypic and anti-idiotypic OKT3 antibodies were assessed by enzyme-linked immunosorbent assay (ELISA), and blocking anti-idiotypic antibodies were detected by immunofluorescence inhibition assay. Positive OKT3 antibody titers were detected in 11 children by ELISA and 10 children by immunfluorescence inhibition assay. In summary, we have found that in pediatric renal transplant patients receiving OKT3 induction therapy: (1) there is a high occurrence of vascular thrombosis; (2) the incidence of early acute rejection is high; (3) the time to first rejection is not as long as that reported for adults: (4) there is a substantial rate of sensitization against OKT3; (4) despite successful reversal of early acute rejection, long-term graft survival does not appear to have bene beneficially altered.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 009116662

Download citation: RISBibTeXText

PMID: 8382505

DOI: 10.1007/bf00861565


Related references

A randomized multicenter trial of OKT3 mAbs induction compared with intravenous cyclosporine in pediatric renal transplantation. Pediatric Transplantation 9(3): 282-292, 2005

Induction vs non induction therapy-OKT3/MALG, ATG in renal transplantation outcome and cost analysis. Journal of the American Society of Nephrology 6(3): 1070, 1995

OKT3 induction in pediatric renal transplant recipients. Pediatric Nephrology 6(5): C143, 1992

OKT3 vs ATG induction in pediatric cadaver renal transplant. Journal of the American Society of Nephrology 3(3): 852, 1992

Mycophenolate mofetil in pediatric renal transplantation without induction therapy: results after 12 months of treatment. German Pediatric Renal Transplantation Study Group. Transplantation 71(5): 638-644, 2001

Induction therapy for pediatric and adult heart transplantation: comparison between OKT3 and daclizumab. Transplantation 80(4): 477-481, 2005

Okt3 induction immunosuppression iirx and immunologic monitoring following pediatric liver transplantation lt. Clinical and Investigative Medicine 15(4 Suppl.): A155, 1992

Results of renal transplantation with OKT3 induction therapy. Journal of the American Society of Nephrology 3(3): 853, 1992

Cytomegalovirus cmv infection as a complication of okt3 therapy in pediatric renal transplantation. Pediatric Researchpart 2: 485a, 1987

Use of sequential ATGAM and OKT3 induction in cadaveric renal transplantation. Journal of the American Society of Nephrology 9(PROGRAM AND ABSTR ISSUE): 680A-681A, 1997

Short course OKT3 induction therapy for 1 degree cadaveric renal transplantation. Journal of the American Society of Nephrology 4(3): 938, 1993

Is the routine use of induction immunosuppression with ALG or OKT3 justified in cadaveric renal transplantation?. Transplantation Proceedings 25(1 Pt 1): 575-576, 1993

OKT3 induction therapy in renal transplantation, outcome and cost analysis. Journal of the American Society of Nephrology 6(3): 1115, 1995

Basiliximab plus low-dose cyclosporin vs. OKT3 for induction immunosuppression following renal transplantation. Clinical Transplantation 17(4): 369-376, 2003